Introduction: The amount of time and money invested into cancer drug research, development, and clinical trials has continually increased over the past few decades. Despite record high cancer drug approval rates, cancer remains a leading cause of death. This suggests the need for more effective tools to help bring novel therapies to clinical practice in a timely manner. Areas covered: In this review, current issues associated with clinical trials are discussed, specifically focusing on poor accrual rates and time for trial completion. In addition, details regarding preclinical studies required before advancing to clinical trials are discussed, including advantages and limitations of current preclinical animal cancer models and their relevance to human cancer trials. Finally, new translational porcine cancer models (Oncopig Cancer Model (OCM)) are presented as potential co-clinical trial models. Expert opinion: In order to address issues impacting the poor success rate of oncology clinical trials, we propose the incorporation of the transformative OCM ‘co-clinical trial’ pathway into the cancer drug approval process. Due to the Oncopig’s high homology to humans and similar tumor phenotypes, their utilization can provide improved preclinical prediction of both drug safety and efficacy prior to investing significant time and money in human clinical trials.

Original languageEnglish (US)
JournalExpert Opinion on Drug Discovery
StateAccepted/In press - Jan 1 2020


  • Cancer Models
  • clinical needs
  • oncology
  • oncopig
  • pigs
  • translational Medicine

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'Porcine cancer models: potential tools to enhance cancer drug trials'. Together they form a unique fingerprint.

  • Cite this